Stem definition | Drug id | CAS RN |
---|---|---|
dipeptidyl aminopeptidase-IV inhibitors | 4175 | 668270-12-0 |
Dose | Unit | Route |
---|---|---|
5 | mg | O |
Property | Value | Reference |
---|---|---|
Vd (Volume of distribution) | 16 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 1.90 mL/min/kg | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 129 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
May 2, 2011 | FDA | BOEHRINGER INGELHEIM | |
July 1, 2011 | PMDA | Nippon Boehringer Ingelheim Co., Ltd |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pemphigoid | 202.25 | 14.89 | 69 | 11797 | 5838 | 50587420 |
Hypoglycaemia | 201.14 | 14.89 | 136 | 11730 | 53445 | 50539813 |
Pancreatitis | 166.68 | 14.89 | 111 | 11755 | 42503 | 50550755 |
Blood glucose increased | 143.65 | 14.89 | 125 | 11741 | 71199 | 50522059 |
Glycosylated haemoglobin increased | 90.78 | 14.89 | 46 | 11820 | 10560 | 50582698 |
Acute kidney injury | 87.78 | 14.89 | 176 | 11690 | 227882 | 50365376 |
Renal impairment | 87.50 | 14.89 | 98 | 11768 | 75563 | 50517695 |
Hyperglycaemia | 79.73 | 14.89 | 67 | 11799 | 36338 | 50556920 |
Dermatitis bullous | 69.94 | 14.89 | 34 | 11832 | 7139 | 50586119 |
Hyperlactacidaemia | 66.34 | 14.89 | 24 | 11842 | 2409 | 50590849 |
Hyperkalaemia | 56.78 | 14.89 | 63 | 11803 | 48026 | 50545232 |
Pancreatic carcinoma | 56.25 | 14.89 | 28 | 11838 | 6186 | 50587072 |
Diabetic ketoacidosis | 54.49 | 14.89 | 40 | 11826 | 17832 | 50575426 |
Diabetes mellitus inadequate control | 53.16 | 14.89 | 35 | 11831 | 13110 | 50580148 |
Metabolic acidosis | 53.12 | 14.89 | 55 | 11811 | 38770 | 50554488 |
Euglycaemic diabetic ketoacidosis | 48.87 | 14.89 | 20 | 11846 | 2799 | 50590459 |
Blood glucose abnormal | 48.66 | 14.89 | 26 | 11840 | 6646 | 50586612 |
Pain | 47.26 | 14.89 | 40 | 11826 | 578863 | 50014395 |
Pancreatitis acute | 46.38 | 14.89 | 41 | 11825 | 23771 | 50569487 |
Cardiac failure | 45.06 | 14.89 | 71 | 11795 | 75969 | 50517289 |
Chronic kidney disease | 45.05 | 14.89 | 51 | 11815 | 39720 | 50553538 |
Glomerular filtration rate decreased | 44.65 | 14.89 | 30 | 11836 | 11622 | 50581636 |
Diabetic metabolic decompensation | 41.85 | 14.89 | 15 | 11851 | 1465 | 50591793 |
Lactic acidosis | 41.62 | 14.89 | 45 | 11821 | 33310 | 50559948 |
Subarachnoid haemorrhage | 39.51 | 14.89 | 27 | 11839 | 10749 | 50582509 |
Renal failure | 39.35 | 14.89 | 81 | 11785 | 106552 | 50486706 |
Dizziness | 38.63 | 14.89 | 172 | 11694 | 346197 | 50247061 |
Drug ineffective | 32.07 | 14.89 | 93 | 11773 | 819240 | 49774018 |
Blood glucose decreased | 30.85 | 14.89 | 29 | 11837 | 18182 | 50575076 |
Lethargy | 29.05 | 14.89 | 46 | 11820 | 49386 | 50543872 |
Urine calcium/creatinine ratio increased | 26.20 | 14.89 | 6 | 11860 | 114 | 50593144 |
Hypoglycaemic encephalopathy | 25.80 | 14.89 | 7 | 11859 | 271 | 50592987 |
Mucosal membrane hyperplasia | 25.49 | 14.89 | 5 | 11861 | 43 | 50593215 |
Rheumatoid arthritis | 25.31 | 14.89 | 8 | 11858 | 202542 | 50390716 |
Ketoacidosis | 25.14 | 14.89 | 14 | 11852 | 3881 | 50589377 |
Shock | 24.26 | 14.89 | 27 | 11839 | 20623 | 50572635 |
Insulin-like growth factor decreased | 23.75 | 14.89 | 7 | 11859 | 367 | 50592891 |
Bite | 23.62 | 14.89 | 7 | 11859 | 374 | 50592884 |
Albuminuria | 23.19 | 14.89 | 6 | 11860 | 193 | 50593065 |
Systemic lupus erythematosus | 22.82 | 14.89 | 3 | 11863 | 140619 | 50452639 |
Blood creatinine increased | 22.57 | 14.89 | 53 | 11813 | 76107 | 50517151 |
Decreased appetite | 22.49 | 14.89 | 100 | 11766 | 200823 | 50392435 |
Urethral caruncle | 22.42 | 14.89 | 5 | 11861 | 84 | 50593174 |
Contraindicated product administered | 22.30 | 14.89 | 4 | 11862 | 148954 | 50444304 |
Altered state of consciousness | 21.32 | 14.89 | 26 | 11840 | 21884 | 50571374 |
Parathyroid hyperplasia | 19.96 | 14.89 | 5 | 11861 | 141 | 50593117 |
Urinary tract infection | 19.68 | 14.89 | 104 | 11762 | 223916 | 50369342 |
Lipase increased | 19.26 | 14.89 | 16 | 11850 | 8525 | 50584733 |
Hypomagnesaemia | 18.62 | 14.89 | 25 | 11841 | 23131 | 50570127 |
Blood potassium increased | 18.51 | 14.89 | 21 | 11845 | 16377 | 50576881 |
Arthropathy | 18.40 | 14.89 | 7 | 11859 | 157899 | 50435359 |
Drug intolerance | 17.97 | 14.89 | 15 | 11851 | 219089 | 50374169 |
Mesenteric vein thrombosis | 17.76 | 14.89 | 7 | 11859 | 889 | 50592369 |
Therapeutic product effect decreased | 17.67 | 14.89 | 5 | 11861 | 136045 | 50457213 |
Rhabdomyolysis | 17.23 | 14.89 | 32 | 11834 | 38995 | 50554263 |
Pyelonephritis | 16.59 | 14.89 | 19 | 11847 | 14970 | 50578288 |
Pemphigus | 16.39 | 14.89 | 4 | 11862 | 120162 | 50473096 |
Food refusal | 16.04 | 14.89 | 5 | 11861 | 317 | 50592941 |
Pancreatic enzymes increased | 16.03 | 14.89 | 6 | 11860 | 662 | 50592596 |
Hypophagia | 15.19 | 14.89 | 25 | 11841 | 27703 | 50565555 |
Pruritus | 15.15 | 14.89 | 116 | 11750 | 283452 | 50309806 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pemphigoid | 473.21 | 14.60 | 169 | 15003 | 7412 | 29551943 |
Pancreatitis | 180.27 | 14.60 | 146 | 15026 | 34368 | 29524987 |
Hypoglycaemia | 163.69 | 14.60 | 160 | 15012 | 48186 | 29511169 |
Glycosylated haemoglobin increased | 127.43 | 14.60 | 72 | 15100 | 9354 | 29550001 |
Dermatitis bullous | 116.34 | 14.60 | 58 | 15114 | 5848 | 29553507 |
Blood glucose increased | 108.21 | 14.60 | 142 | 15030 | 58842 | 29500513 |
Cardiac failure | 76.55 | 14.60 | 142 | 15030 | 79145 | 29480210 |
Blood mercury abnormal | 74.51 | 14.60 | 18 | 15154 | 189 | 29559166 |
5-hydroxyindolacetic acid in urine increased | 72.47 | 14.60 | 18 | 15154 | 214 | 29559141 |
Pericardial disease | 63.57 | 14.60 | 18 | 15154 | 364 | 29558991 |
Left ventricular dysfunction | 62.57 | 14.60 | 45 | 15127 | 8857 | 29550498 |
Pulmonary valve disease | 58.57 | 14.60 | 16 | 15156 | 282 | 29559073 |
Euglycaemic diabetic ketoacidosis | 58.29 | 14.60 | 28 | 15144 | 2602 | 29556753 |
Diastolic dysfunction | 50.98 | 14.60 | 32 | 15140 | 5032 | 29554323 |
Cerebral infarction | 47.66 | 14.60 | 61 | 15111 | 24614 | 29534741 |
Low density lipoprotein decreased | 46.22 | 14.60 | 18 | 15154 | 1002 | 29558353 |
Ventricular hyperkinesia | 44.39 | 14.60 | 12 | 15160 | 203 | 29559152 |
Mean platelet volume increased | 43.99 | 14.60 | 14 | 15158 | 427 | 29558928 |
Pancreatic carcinoma | 43.19 | 14.60 | 33 | 15139 | 7117 | 29552238 |
Right atrial enlargement | 43.13 | 14.60 | 12 | 15160 | 227 | 29559128 |
Hyperglycaemia | 42.99 | 14.60 | 69 | 15103 | 34218 | 29525137 |
Renal impairment | 42.48 | 14.60 | 114 | 15058 | 81219 | 29478136 |
Stenosis | 42.37 | 14.60 | 17 | 15155 | 1024 | 29558331 |
Rales | 41.76 | 14.60 | 33 | 15139 | 7477 | 29551878 |
Physical examination abnormal | 41.47 | 14.60 | 12 | 15160 | 263 | 29559092 |
Diabetic nephropathy | 41.46 | 14.60 | 20 | 15152 | 1875 | 29557480 |
Diabetic ketoacidosis | 41.37 | 14.60 | 46 | 15126 | 16027 | 29543328 |
Acute kidney injury | 41.06 | 14.60 | 254 | 14918 | 265013 | 29294342 |
Hypochromasia | 40.09 | 14.60 | 12 | 15160 | 297 | 29559058 |
Hepatic neoplasm | 39.04 | 14.60 | 19 | 15153 | 1817 | 29557538 |
Pancreatitis acute | 39.02 | 14.60 | 55 | 15117 | 24330 | 29535025 |
Mitral valve thickening | 37.86 | 14.60 | 12 | 15160 | 361 | 29558994 |
Tricuspid valve incompetence | 36.51 | 14.60 | 32 | 15140 | 8362 | 29550993 |
Cardiac discomfort | 34.99 | 14.60 | 12 | 15160 | 464 | 29558891 |
Blood glucose abnormal | 31.89 | 14.60 | 24 | 15148 | 5059 | 29554296 |
Left ventricular enlargement | 31.30 | 14.60 | 12 | 15160 | 640 | 29558715 |
Chronic kidney disease | 31.12 | 14.60 | 62 | 15110 | 36354 | 29523001 |
Drug abuse | 30.19 | 14.60 | 3 | 15169 | 79880 | 29479475 |
Necrotising oesophagitis | 30.14 | 14.60 | 11 | 15161 | 511 | 29558844 |
Left atrial enlargement | 29.62 | 14.60 | 12 | 15160 | 741 | 29558614 |
Mucosal dryness | 29.18 | 14.60 | 13 | 15159 | 1016 | 29558339 |
Neoplasm | 29.16 | 14.60 | 21 | 15151 | 4140 | 29555215 |
Mitral valve incompetence | 29.09 | 14.60 | 35 | 15137 | 13258 | 29546097 |
Bundle branch block left | 28.93 | 14.60 | 23 | 15149 | 5254 | 29554101 |
Expired product administered | 28.89 | 14.60 | 18 | 15154 | 2793 | 29556562 |
Haematocrit increased | 28.49 | 14.60 | 15 | 15157 | 1693 | 29557662 |
Pericardial haemorrhage | 28.20 | 14.60 | 18 | 15154 | 2913 | 29556442 |
Completed suicide | 28.09 | 14.60 | 6 | 15166 | 90240 | 29469115 |
Mitral valve disease | 27.17 | 14.60 | 13 | 15159 | 1197 | 29558158 |
Aortic valve incompetence | 25.68 | 14.60 | 21 | 15151 | 4992 | 29554363 |
Ventricular arrhythmia | 25.10 | 14.60 | 20 | 15152 | 4584 | 29554771 |
Echocardiogram abnormal | 24.69 | 14.60 | 11 | 15161 | 860 | 29558495 |
Interstitial lung disease | 24.38 | 14.60 | 75 | 15097 | 57643 | 29501712 |
Hypovolaemia | 24.17 | 14.60 | 25 | 15147 | 8020 | 29551335 |
Haemoglobin increased | 23.57 | 14.60 | 16 | 15156 | 2870 | 29556485 |
Blood iron decreased | 23.56 | 14.60 | 19 | 15153 | 4429 | 29554926 |
Poikilocytosis | 23.55 | 14.60 | 7 | 15165 | 169 | 29559186 |
Diabetes mellitus inadequate control | 23.42 | 14.60 | 30 | 15142 | 12104 | 29547251 |
Hyperkalaemia | 23.40 | 14.60 | 77 | 15095 | 61315 | 29498040 |
Acute lung injury | 23.07 | 14.60 | 12 | 15160 | 1321 | 29558034 |
Left atrial dilatation | 23.05 | 14.60 | 13 | 15159 | 1680 | 29557675 |
Amylase increased | 22.70 | 14.60 | 20 | 15152 | 5260 | 29554095 |
Hypohidrosis | 22.70 | 14.60 | 7 | 15165 | 192 | 29559163 |
Hypoglycaemic coma | 22.61 | 14.60 | 14 | 15158 | 2149 | 29557206 |
Glomerular filtration rate decreased | 21.98 | 14.60 | 28 | 15144 | 11238 | 29548117 |
Bronchitis viral | 21.95 | 14.60 | 7 | 15165 | 215 | 29559140 |
Eosinophilic pneumonia | 21.41 | 14.60 | 15 | 15157 | 2831 | 29556524 |
Peak expiratory flow rate decreased | 21.25 | 14.60 | 6 | 15166 | 120 | 29559235 |
Electrocardiogram T wave inversion | 21.06 | 14.60 | 13 | 15159 | 1984 | 29557371 |
Hypertensive heart disease | 20.42 | 14.60 | 13 | 15159 | 2094 | 29557261 |
Hepatojugular reflux | 20.13 | 14.60 | 8 | 15164 | 470 | 29558885 |
Red blood cell count decreased | 19.99 | 14.60 | 42 | 15130 | 25560 | 29533795 |
Diabetic ketoacidotic hyperglycaemic coma | 19.98 | 14.60 | 6 | 15166 | 150 | 29559205 |
Supraventricular tachycardia | 19.97 | 14.60 | 25 | 15147 | 9859 | 29549496 |
Dyspnoea at rest | 19.78 | 14.60 | 15 | 15157 | 3199 | 29556156 |
Electrocardiogram Q wave abnormal | 19.54 | 14.60 | 7 | 15165 | 308 | 29559047 |
Blindness transient | 18.99 | 14.60 | 12 | 15160 | 1908 | 29557447 |
Occult blood | 18.77 | 14.60 | 8 | 15164 | 562 | 29558793 |
Drug ineffective | 18.54 | 14.60 | 110 | 15062 | 363060 | 29196295 |
Hepatic function abnormal | 18.46 | 14.60 | 53 | 15119 | 39206 | 29520149 |
Lipase increased | 18.32 | 14.60 | 22 | 15150 | 8315 | 29551040 |
Rhinalgia | 18.26 | 14.60 | 7 | 15165 | 373 | 29558982 |
Respiratory symptom | 17.77 | 14.60 | 9 | 15163 | 937 | 29558418 |
Hyperlactacidaemia | 17.59 | 14.60 | 13 | 15159 | 2665 | 29556690 |
Blood chloride increased | 17.46 | 14.60 | 13 | 15159 | 2696 | 29556659 |
Haemodynamic instability | 17.24 | 14.60 | 21 | 15151 | 8052 | 29551303 |
Bronchial hyperreactivity | 17.02 | 14.60 | 10 | 15162 | 1396 | 29557959 |
Blood phosphorus increased | 16.93 | 14.60 | 13 | 15159 | 2824 | 29556531 |
Left ventricular hypertrophy | 16.92 | 14.60 | 19 | 15153 | 6684 | 29552671 |
Helicobacter gastritis | 16.79 | 14.60 | 9 | 15163 | 1053 | 29558302 |
Epidermolysis | 16.71 | 14.60 | 6 | 15166 | 266 | 29559089 |
Intestinal obstruction | 16.67 | 14.60 | 33 | 15139 | 19244 | 29540111 |
Hyperaesthesia teeth | 16.65 | 14.60 | 7 | 15165 | 475 | 29558880 |
General physical health deterioration | 16.55 | 14.60 | 17 | 15155 | 102840 | 29456515 |
Dust allergy | 16.55 | 14.60 | 7 | 15165 | 482 | 29558873 |
Syncope | 16.54 | 14.60 | 84 | 15088 | 81287 | 29478068 |
Marasmus | 16.47 | 14.60 | 7 | 15165 | 488 | 29558867 |
Gastric cancer | 16.43 | 14.60 | 16 | 15156 | 4778 | 29554577 |
Erythema multiforme | 16.36 | 14.60 | 20 | 15152 | 7697 | 29551658 |
High density lipoprotein decreased | 16.36 | 14.60 | 13 | 15159 | 2966 | 29556389 |
Off label use | 15.93 | 14.60 | 90 | 15082 | 300710 | 29258645 |
Blood uric acid increased | 15.69 | 14.60 | 17 | 15155 | 5751 | 29553604 |
Product use in unapproved indication | 15.58 | 14.60 | 13 | 15159 | 86862 | 29472493 |
Carotid artery stenosis | 15.47 | 14.60 | 15 | 15157 | 4454 | 29554901 |
Eosinophil count increased | 15.47 | 14.60 | 19 | 15153 | 7350 | 29552005 |
Skin disorder | 15.40 | 14.60 | 24 | 15148 | 11594 | 29547761 |
Lactic acidosis | 15.36 | 14.60 | 42 | 15130 | 30205 | 29529150 |
Pain | 14.98 | 14.60 | 42 | 15130 | 171390 | 29387965 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pemphigoid | 649.97 | 13.51 | 228 | 24493 | 12758 | 64461253 |
Hypoglycaemia | 323.53 | 13.51 | 271 | 24450 | 89621 | 64384390 |
Pancreatitis | 227.42 | 13.51 | 186 | 24535 | 59421 | 64414590 |
Glycosylated haemoglobin increased | 174.26 | 13.51 | 96 | 24625 | 15923 | 64458088 |
Blood glucose increased | 169.10 | 13.51 | 198 | 24523 | 97875 | 64376136 |
Dermatitis bullous | 133.20 | 13.51 | 73 | 24648 | 11981 | 64462030 |
Acute kidney injury | 129.76 | 13.51 | 422 | 24299 | 448818 | 64025193 |
Cardiac failure | 125.53 | 13.51 | 200 | 24521 | 132173 | 64341838 |
Renal impairment | 105.36 | 13.51 | 187 | 24534 | 134830 | 64339181 |
Euglycaemic diabetic ketoacidosis | 104.93 | 13.51 | 48 | 24673 | 5362 | 64468649 |
Diabetic ketoacidosis | 99.04 | 13.51 | 86 | 24635 | 29759 | 64444252 |
Hyperglycaemia | 98.26 | 13.51 | 119 | 24602 | 60849 | 64413162 |
Pancreatic carcinoma | 90.90 | 13.51 | 54 | 24667 | 10319 | 64463692 |
Chronic kidney disease | 82.06 | 13.51 | 106 | 24615 | 57813 | 64416198 |
Blood mercury abnormal | 79.73 | 13.51 | 18 | 24703 | 189 | 64473822 |
5-hydroxyindolacetic acid in urine increased | 77.53 | 13.51 | 18 | 24703 | 216 | 64473795 |
Diabetes mellitus inadequate control | 71.87 | 13.51 | 62 | 24659 | 21259 | 64452752 |
Hyperkalaemia | 69.92 | 13.51 | 133 | 24588 | 100996 | 64373015 |
Hyperlactacidaemia | 69.66 | 13.51 | 35 | 24686 | 4809 | 64469202 |
Pain | 67.20 | 13.51 | 68 | 24653 | 553443 | 63920568 |
Pulmonary valve disease | 65.18 | 13.51 | 16 | 24705 | 247 | 64473764 |
Completed suicide | 64.17 | 13.51 | 6 | 24715 | 224408 | 64249603 |
Pericardial disease | 63.82 | 13.51 | 18 | 24703 | 486 | 64473525 |
Glomerular filtration rate decreased | 60.14 | 13.51 | 54 | 24667 | 19518 | 64454493 |
Drug ineffective | 56.52 | 13.51 | 152 | 24569 | 840095 | 63633916 |
Pancreatitis acute | 55.39 | 13.51 | 75 | 24646 | 42780 | 64431231 |
Metabolic acidosis | 53.64 | 13.51 | 97 | 24624 | 70861 | 64403150 |
Left ventricular dysfunction | 52.53 | 13.51 | 47 | 24674 | 16907 | 64457104 |
Cerebral infarction | 51.79 | 13.51 | 71 | 24650 | 40973 | 64433038 |
Low density lipoprotein decreased | 50.16 | 13.51 | 18 | 24703 | 1072 | 64472939 |
Lactic acidosis | 49.05 | 13.51 | 86 | 24635 | 61324 | 64412687 |
Diabetic nephropathy | 46.65 | 13.51 | 22 | 24699 | 2632 | 64471379 |
Physical examination abnormal | 45.73 | 13.51 | 12 | 24709 | 245 | 64473766 |
Diastolic dysfunction | 45.40 | 13.51 | 33 | 24688 | 8842 | 64465169 |
Blood glucose abnormal | 45.28 | 13.51 | 33 | 24688 | 8880 | 64465131 |
Ventricular hyperkinesia | 45.01 | 13.51 | 12 | 24709 | 261 | 64473750 |
Renal failure | 42.90 | 13.51 | 160 | 24561 | 181528 | 64292483 |
Right atrial enlargement | 42.58 | 13.51 | 12 | 24709 | 323 | 64473688 |
Mitral valve thickening | 40.45 | 13.51 | 12 | 24709 | 389 | 64473622 |
Drug abuse | 39.30 | 13.51 | 3 | 24718 | 132371 | 64341640 |
Stenosis | 38.04 | 13.51 | 17 | 24704 | 1798 | 64472213 |
Interstitial lung disease | 37.72 | 13.51 | 102 | 24619 | 97630 | 64376381 |
Mean platelet volume increased | 37.06 | 13.51 | 14 | 24707 | 964 | 64473047 |
Hepatic neoplasm | 35.00 | 13.51 | 19 | 24702 | 3058 | 64470953 |
Hypochromasia | 34.57 | 13.51 | 12 | 24709 | 648 | 64473363 |
Blood iron decreased | 34.37 | 13.51 | 32 | 24689 | 12110 | 64461901 |
Diabetic metabolic decompensation | 34.28 | 13.51 | 18 | 24703 | 2710 | 64471301 |
Left ventricular enlargement | 34.15 | 13.51 | 12 | 24709 | 672 | 64473339 |
Ketoacidosis | 33.93 | 13.51 | 25 | 24696 | 6838 | 64467173 |
Cardiac discomfort | 32.12 | 13.51 | 13 | 24708 | 1076 | 64472935 |
Rales | 31.77 | 13.51 | 34 | 24687 | 15195 | 64458816 |
Product use in unapproved indication | 31.69 | 13.51 | 14 | 24707 | 176604 | 64297407 |
Haemodynamic instability | 30.59 | 13.51 | 33 | 24688 | 14879 | 64459132 |
Necrotising oesophagitis | 30.27 | 13.51 | 11 | 24710 | 679 | 64473332 |
Left atrial enlargement | 29.35 | 13.51 | 12 | 24709 | 1020 | 64472991 |
Altered state of consciousness | 28.87 | 13.51 | 52 | 24669 | 37850 | 64436161 |
Tricuspid valve incompetence | 28.70 | 13.51 | 34 | 24687 | 16969 | 64457042 |
Therapeutic product effect decreased | 28.35 | 13.51 | 5 | 24716 | 115346 | 64358665 |
Haematocrit increased | 28.23 | 13.51 | 17 | 24704 | 3328 | 64470683 |
Expired product administered | 27.79 | 13.51 | 21 | 24700 | 5966 | 64468045 |
Pericardial haemorrhage | 27.32 | 13.51 | 18 | 24703 | 4118 | 64469893 |
Left ventricular hypertrophy | 26.80 | 13.51 | 25 | 24696 | 9481 | 64464530 |
Hypoglycaemic coma | 26.79 | 13.51 | 18 | 24703 | 4256 | 64469755 |
Treatment failure | 26.74 | 13.51 | 6 | 24715 | 116810 | 64357201 |
Blood phosphorus increased | 26.69 | 13.51 | 19 | 24702 | 4927 | 64469084 |
End stage renal disease | 26.60 | 13.51 | 26 | 24695 | 10449 | 64463562 |
Lipase increased | 26.32 | 13.51 | 30 | 24691 | 14372 | 64459639 |
Arthropathy | 26.16 | 13.51 | 7 | 24714 | 120960 | 64353051 |
Hepatic function abnormal | 25.69 | 13.51 | 68 | 24653 | 64245 | 64409766 |
Rheumatoid arthritis | 25.09 | 13.51 | 16 | 24705 | 164278 | 64309733 |
Synovitis | 25 | 13.51 | 4 | 24717 | 99086 | 64374925 |
Subarachnoid haemorrhage | 24.94 | 13.51 | 33 | 24688 | 18405 | 64455606 |
Neoplasm | 24.82 | 13.51 | 21 | 24700 | 7010 | 64467001 |
Drug hypersensitivity | 24.69 | 13.51 | 33 | 24688 | 237782 | 64236229 |
Amylase increased | 24.52 | 13.51 | 24 | 24697 | 9661 | 64464350 |
Diabetic ketoacidotic hyperglycaemic coma | 23.86 | 13.51 | 7 | 24714 | 218 | 64473793 |
Ventricular arrhythmia | 23.85 | 13.51 | 21 | 24700 | 7394 | 64466617 |
Infusion related reaction | 23.80 | 13.51 | 17 | 24704 | 164450 | 64309561 |
Bundle branch block left | 23.80 | 13.51 | 24 | 24697 | 10010 | 64464001 |
Renal disorder | 23.78 | 13.51 | 46 | 24675 | 35319 | 64438692 |
Aortic valve incompetence | 23.73 | 13.51 | 22 | 24699 | 8279 | 64465732 |
Haemoglobin increased | 23.61 | 13.51 | 18 | 24703 | 5183 | 64468828 |
Hypohidrosis | 23.59 | 13.51 | 7 | 24714 | 227 | 64473784 |
Headache | 23.35 | 13.51 | 114 | 24607 | 529353 | 63944658 |
Mitral valve incompetence | 23.35 | 13.51 | 38 | 24683 | 25500 | 64448511 |
Diabetes mellitus | 23.29 | 13.51 | 67 | 24654 | 66407 | 64407604 |
Mucosal membrane hyperplasia | 22.94 | 13.51 | 5 | 24716 | 44 | 64473967 |
Blood creatinine increased | 22.23 | 13.51 | 107 | 24614 | 135675 | 64338336 |
Poikilocytosis | 22.14 | 13.51 | 7 | 24714 | 282 | 64473729 |
Gastric cancer | 22.12 | 13.51 | 19 | 24702 | 6474 | 64467537 |
Arthralgia | 22.03 | 13.51 | 91 | 24630 | 442169 | 64031842 |
Urine calcium/creatinine ratio increased | 22.03 | 13.51 | 6 | 24715 | 142 | 64473869 |
Hepatojugular reflux | 21.64 | 13.51 | 8 | 24713 | 519 | 64473492 |
Mitral valve disease | 21.22 | 13.51 | 13 | 24708 | 2625 | 64471386 |
Erythema multiforme | 21.08 | 13.51 | 28 | 24693 | 15673 | 64458338 |
Marasmus | 21.01 | 13.51 | 9 | 24712 | 859 | 64473152 |
Decreased appetite | 20.70 | 13.51 | 181 | 24540 | 281108 | 64192903 |
Left atrial dilatation | 20.65 | 13.51 | 13 | 24708 | 2753 | 64471258 |
Urethral caruncle | 20.56 | 13.51 | 5 | 24716 | 74 | 64473937 |
Hypoglycaemic encephalopathy | 20.47 | 13.51 | 8 | 24713 | 604 | 64473407 |
Blood uric acid increased | 20.24 | 13.51 | 20 | 24701 | 8143 | 64465868 |
Echocardiogram abnormal | 20.22 | 13.51 | 11 | 24710 | 1778 | 64472233 |
Red blood cell count decreased | 20.18 | 13.51 | 52 | 24669 | 48334 | 64425677 |
Electrocardiogram T wave inversion | 20.18 | 13.51 | 16 | 24705 | 4878 | 64469133 |
Electrocardiogram Q wave abnormal | 19.73 | 13.51 | 7 | 24714 | 403 | 64473608 |
Sputum discoloured | 19.73 | 13.51 | 29 | 24692 | 17827 | 64456184 |
Mucosal dryness | 19.68 | 13.51 | 13 | 24708 | 2988 | 64471023 |
Syncope | 19.50 | 13.51 | 115 | 24606 | 157520 | 64316491 |
Bite | 19.44 | 13.51 | 7 | 24714 | 421 | 64473590 |
Supraventricular tachycardia | 18.47 | 13.51 | 29 | 24692 | 18878 | 64455133 |
Depression | 18.45 | 13.51 | 26 | 24695 | 183265 | 64290746 |
Hypovolaemia | 18.35 | 13.51 | 26 | 24695 | 15460 | 64458551 |
Acute lung injury | 18.32 | 13.51 | 12 | 24709 | 2719 | 64471292 |
Neutropenia | 17.83 | 13.51 | 41 | 24680 | 239583 | 64234428 |
Insulin-like growth factor decreased | 17.63 | 13.51 | 7 | 24714 | 551 | 64473460 |
Diabetic foot | 17.28 | 13.51 | 12 | 24709 | 2993 | 64471018 |
Antibiotic level above therapeutic | 17.00 | 13.51 | 7 | 24714 | 606 | 64473405 |
Acute myocardial infarction | 16.93 | 13.51 | 62 | 24659 | 69656 | 64404355 |
Hypertensive heart disease | 16.90 | 13.51 | 13 | 24708 | 3791 | 64470220 |
Peak expiratory flow rate decreased | 16.83 | 13.51 | 7 | 24714 | 621 | 64473390 |
Parathyroid hyperplasia | 16.77 | 13.51 | 5 | 24716 | 165 | 64473846 |
Albuminuria | 16.58 | 13.51 | 7 | 24714 | 645 | 64473366 |
High density lipoprotein decreased | 16.48 | 13.51 | 13 | 24708 | 3933 | 64470078 |
Nephrogenic anaemia | 16.19 | 13.51 | 12 | 24709 | 3313 | 64470698 |
Cardiomegaly | 16.16 | 13.51 | 31 | 24690 | 23653 | 64450358 |
Toxicity to various agents | 16.15 | 13.51 | 78 | 24643 | 363435 | 64110576 |
Carotid arteriosclerosis | 16.10 | 13.51 | 10 | 24711 | 2069 | 64471942 |
Pruritus | 15.75 | 13.51 | 186 | 24535 | 312214 | 64161797 |
Eosinophil count increased | 15.71 | 13.51 | 23 | 24698 | 14089 | 64459922 |
Femoral neck fracture | 15.65 | 13.51 | 18 | 24703 | 8706 | 64465305 |
Arteriosclerosis coronary artery | 15.42 | 13.51 | 24 | 24697 | 15505 | 64458506 |
Rhinalgia | 15.39 | 13.51 | 8 | 24713 | 1180 | 64472831 |
Drug eruption | 15.24 | 13.51 | 39 | 24682 | 36097 | 64437914 |
Alopecia | 15.23 | 13.51 | 25 | 24696 | 165665 | 64308346 |
Hypersensitivity | 15.11 | 13.51 | 33 | 24688 | 196419 | 64277592 |
Epidermolysis | 15.09 | 13.51 | 6 | 24715 | 474 | 64473537 |
Hyperuricaemia | 14.97 | 13.51 | 19 | 24702 | 10172 | 64463839 |
Drug intolerance | 14.94 | 13.51 | 31 | 24690 | 187961 | 64286050 |
Dyspnoea at rest | 14.76 | 13.51 | 15 | 24706 | 6314 | 64467697 |
Contraindicated product administered | 14.51 | 13.51 | 12 | 24709 | 107817 | 64366194 |
Haematocrit decreased | 14.46 | 13.51 | 50 | 24671 | 54605 | 64419406 |
Serum ferritin increased | 14.40 | 13.51 | 17 | 24704 | 8451 | 64465560 |
Sinusitis | 14.38 | 13.51 | 21 | 24700 | 145907 | 64328104 |
Bronchial hyperreactivity | 14.37 | 13.51 | 10 | 24711 | 2502 | 64471509 |
Chills | 14.28 | 13.51 | 19 | 24702 | 137245 | 64336766 |
Blood chloride increased | 14.26 | 13.51 | 13 | 24708 | 4790 | 64469221 |
Blood glucose decreased | 14.25 | 13.51 | 29 | 24692 | 23094 | 64450917 |
Systemic lupus erythematosus | 14.15 | 13.51 | 6 | 24715 | 77606 | 64396405 |
Occult blood | 14.14 | 13.51 | 8 | 24713 | 1394 | 64472617 |
Anxiety | 14.02 | 13.51 | 36 | 24685 | 202613 | 64271398 |
Blindness transient | 13.91 | 13.51 | 12 | 24709 | 4110 | 64469901 |
Intraductal papillary mucinous neoplasm | 13.83 | 13.51 | 6 | 24715 | 591 | 64473420 |
Pneumonia | 13.65 | 13.51 | 295 | 24426 | 559281 | 63914730 |
Pyelonephritis | 13.54 | 13.51 | 24 | 24697 | 17242 | 64456769 |
None
Source | Code | Description |
---|---|---|
ATC | A10BD11 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD19 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BD27 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Combinations of oral blood glucose lowering drugs |
ATC | A10BH05 | ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Dipeptidyl peptidase 4 (DPP-4) inhibitors |
MeSH PA | D054873 | Dipeptidyl-Peptidase IV Inhibitors |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D006728 | Hormones |
MeSH PA | D007004 | Hypoglycemic Agents |
MeSH PA | D054795 | Incretins |
MeSH PA | D011480 | Protease Inhibitors |
FDA MoA | N0000175912 | Dipeptidyl Peptidase 4 Inhibitors |
FDA EPC | N0000175913 | Dipeptidyl Peptidase 4 Inhibitor |
CHEBI has role | CHEBI:35526 | antidiabetic |
CHEBI has role | CHEBI:68612 | dipeptidyl peptidase-4 inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Diabetes mellitus type 2 | indication | 44054006 | DOID:9352 |
Pancreatitis | contraindication | 75694006 | DOID:4989 |
Hypoglycemic disorder | contraindication | 237630007 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.16 | Basic |
pKa2 | 6.13 | Basic |
pKa3 | 3.79 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE) |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONLYUREA |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND/OR PIOGLITAZONE) |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND/OR A SULFONYLUREA |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA) |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN) |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA) |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN) |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8119648 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8178541 | Aug. 12, 2023 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 8673927 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9173859 | May 4, 2027 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10022379 | April 2, 2029 | METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 10034877 | Aug. 5, 2029 | TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 9486526 | Aug. 5, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 8551957 | Oct. 14, 2029 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | 8846695 | June 4, 2030 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10406172 | June 15, 2030 | METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | 8853156 | March 5, 2031 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISINGMETFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10596120 | March 7, 2032 | TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | 9555001 | March 6, 2033 | METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 10258637 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 11090323 | April 3, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML/MIN/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML/MIN/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML/MIN/1.73 M2 |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN |
10MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
12.5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
25MG;5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
5MG;2.5MG;1GM | TRIJARDY XR | BOEHRINGER INGELHEIM | N212614 | Jan. 27, 2020 | RX | TABLET, EXTENDED RELEASE | ORAL | 9949998 | June 11, 2034 | METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML/MIN/1.73 M2<=EGFR<60 ML/MIN/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | July 3, 2022 | INFORMATION ADDED TO THE LABELING TO DESCRIBE CARMELINA TRIAL TO FULFILL POSTMARKETING COMMITMENT 1766-4 |
5MG | TRADJENTA | BOEHRINGER INGELHEIM | N201280 | May 2, 2011 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;1GM | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;500MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;850MG | JENTADUETO | BOEHRINGER INGELHEIM | N201281 | Jan. 30, 2012 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
10MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
25MG;5MG | GLYXAMBI | BOEHRINGER INGELHEIM | N206073 | Jan. 30, 2015 | RX | TABLET | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
2.5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
5MG;1GM | JENTADUETO XR | BOEHRINGER INGELHEIM | N208026 | May 27, 2016 | RX | TABLET, EXTENDED RELEASE | ORAL | March 30, 2023 | ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Dipeptidyl peptidase 4 | Enzyme | INHIBITOR | IC50 | 10 | CHEMBL | CHEMBL | |||
Muscarinic acetylcholine receptor M1 | GPCR | IC50 | 6.53 | CHEMBL | |||||
Prolyl endopeptidase FAP | Enzyme | IC50 | 7.05 | CHEMBL | |||||
Dipeptidyl peptidase 9 | Enzyme | IC50 | 4 | CHEMBL | |||||
Prolyl endopeptidase FAP | Enzyme | IC50 | 6.43 | CHEMBL | |||||
Dipeptidyl peptidase IV | Unclassified | IC50 | 5 | CHEMBL |
ID | Source |
---|---|
4030725 | VUID |
N0000182735 | NUI |
D09566 | KEGG_DRUG |
4030725 | VANDF |
C2746078 | UMLSCUI |
CHEBI:68610 | CHEBI |
356 | PDB_CHEM_ID |
CHEMBL237500 | ChEMBL_ID |
D000069476 | MESH_DESCRIPTOR_UI |
DB08882 | DRUGBANK_ID |
6318 | IUPHAR_LIGAND_ID |
9039 | INN_ID |
3X29ZEJ4R2 | UNII |
10096344 | PUBCHEM_CID |
1100699 | RXNORM |
181237 | MMSL |
27861 | MMSL |
d07767 | MMSL |
013732 | NDDF |
702798009 | SNOMEDCT_US |
703667006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0140 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 33 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0140 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 33 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0146 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0146 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0147 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0147 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0148 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0148 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 34 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0164 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0164 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0182 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Glyxambi | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0182 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 32 sections |
Jentadueto XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0270 | TABLET, FILM COATED, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Jentadueto XR | HUMAN PRESCRIPTION DRUG LABEL | 2 | 0597-0275 | TABLET, FILM COATED, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0380 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0385 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0390 | TABLET, EXTENDED RELEASE | 5 mg | ORAL | NDA | 34 sections |
Trijardy XR | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0597-0395 | TABLET, EXTENDED RELEASE | 2.50 mg | ORAL | NDA | 34 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-4383 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 29 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 54868-6461 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 28 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0410 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 29 sections |
Tradjenta | HUMAN PRESCRIPTION DRUG LABEL | 1 | 55154-0410 | TABLET, FILM COATED | 5 mg | ORAL | NDA | 29 sections |
Jentadueto | HUMAN PRESCRIPTION DRUG LABEL | 2 | 63629-6524 | TABLET, FILM COATED | 2.50 mg | ORAL | NDA | 31 sections |